araag2/HINT huggingface dataset:
Clinical trial NCT02497378 (phase 1, status: completed)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: jnj-54767414 (daratumumab), bortezomib, dexamethasone
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Participants proven to have symptomatic (having symptoms) multiple myeloma (MM)
             according the International Myeloma Working Group (IMWG) diagnostic criteria

          -  Participant must have documented MM as defined by following criteria: Monoclonal
             plasma cells in the bone marrow 10 percent (%), or presence of a biopsy-proven
             plasmacytoma at some point in their disease history, disease measurements: a) Serum
             M-protein greater than or equal to (>=) 1 gram per deciliter (g/dL) (>=10 gram per
             liter [g/L]) b) Serum immunoglobulin A [IgA] M-protein >= 0.5 g/dL); c) Urine
             M-protein >=200 milligram per 24 hour (mg/24 h); d) Serum immunoglobulin free light
             chain >=10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio

          -  Participant must have received at least 1 prior line of therapy for MM

          -  Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status
             score of 0 or 1

          -  Participant must have achieved a response (partial response [PR] or better based on
             investigator's determination of response by the IMWG criteria) to at least 1 prior
             regimen

        Exclusion Criteria:

          -  Participant has received daratumumab or other anti-cluster of differentiation 38
             (anti-CD38) therapies previously

          -  Is refractory to bortezomib or another PI, like ixazomib and carfilzomib (had
             progression of disease while receiving bortezomib therapy or within 60 days of ending
             bortezomib therapy or another PI therapy, like ixazomib and carfilzomib

          -  Is intolerant to bortezomib (ie, discontinued due to any adverse event while on
             bortezomib treatment)

          -  Has received anti-myeloma treatment within 2 weeks or 5 pharmacokinetic half-lives of
             the treatment, whichever is longer, before the date of daratumumab first
             administration. The only exception is emergency use of a short course of
             corticosteroids (equivalent of dexamethasone 40 milligram per day [mg/day] for a
             maximum of 4 days) before treatment. A list of anti-myeloma treatments with the
             corresponding pharmacokinetic half-lives is provided in the Site Investigational
             Product Procedures Manual (IPPM)

          -  Has a history of malignancy (other than multiple myeloma) within 3 years before the
             date of daratumumab first administration

          -  Has any concurrent medical condition or disease (eg, active systemic infection,
             pulmonary impairment) that is likely to interfere with study procedures
Clinical trial NCT02499770 (phase 1/phase 2, status: completed)
Conditions: small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: carboplatin, placebo, trilaciclib, etoposide
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects aged ≥18 years

          -  Unequivocally confirmed diagnosis of SCLC by histology or cytology, preferably
             including the presence of neuroendocrine features by immunohistochemistry

          -  At least 1 target lesion that is unirradiated and measurable by RECIST, Version 1.1

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2

          -  Adequate organ function

        Exclusion Criteria:

          -  Prior chemotherapy for extensive-stage SCLC

          -  Presence of symptomatic brain metastases requiring immediate treatment with radiation
             therapy or steroids.

          -  Uncontrolled ischemic heart disease or uncontrolled symptomatic congestive heart
             failure

          -  Known history of stroke or cerebrovascular accident within 6 months prior to
             enrollment

          -  Other uncontrolled serious chronic disease or conditions that in the investigator's
             opinion could affect compliance or follow-up in the protocol

          -  Concurrent radiotherapy to any site or radiotherapy within 2 weeks prior to enrollment
             or previous radiotherapy to the target lesion sites (the sites that are to be followed
             for determination of a response)

          -  Receipt of any investigational medication within 4 weeks prior to enrollment
Clinical trial NCT02499874 (phase 1, status: completed)
Conditions: hiv
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: efavirenz, tenofovir /emtricitabine, tenofovir/lamivudine, lamivudine/zidovudine
SMILES: [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Evidence of a personally signed and dated informed consent document indicating that
             the participant has been informed of all pertinent aspects of the study.

          2. HIV-1-infected pregnant female, stable on two nucleos/tide analogues
             (tenofovir/emtricitabine or tenofovir/lamivudine or zidovudine/lamivudine) and
             efavirenz 600mg once daily for more than 12 weeks and willing to take efavirenz 400 mg
             once daily at gestational age of 28 weeks +/- 3 weeks.

          3. Undetectable viral load (by local assay).

          4. CD4 count > 100 cells/mm3.

          5. Aged between 18 to 45 years, inclusive.

        Exclusion Criteria:

          1. Viral load ≥ 50 copies/mL (or detectable by local assay).

          2. Evidence of organ dysfunction or any clinically significant deviation from normal in
             physical examination, vital signs, ECG or clinical laboratory determinations.

          3. Positive blood screen for chronic hepatitis C (if available locally) or hepatitis B.

          4. Current or recent (within 3 months) gastrointestinal disease.

          5. Clinically relevant alcohol or drug use (positive urine drug screen) or history of
             alcohol or drug use considered by the Investigator to be sufficient to hinder
             compliance with treatment, follow-up procedures or evaluation of adverse events.

          6. Exposure to any investigational drug or placebo within 3 months prior to first dose of
             study drug.

          7. Use of any other drugs, including over-the-counter medications and herbal
             preparations, within two weeks prior to first dose of study drug, unless
             approved/prescribed by the Principal Investigator as known not to interact with study
             drugs.
Clinical trial NCT02504554 (phase 1/phase 2, status: completed)
Conditions: gastrointestinal problems, autism spectrum disorders
ICD codes: A21.3, A22.2, B46.2, K92.2, K92.81, K91.0, P54.3, Z16.12
Drugs: oral vancomycin, moviprep, prilosec
SMILES: CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2, [Na+].[Cl-], COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C
Eligibility criteria:

        Inclusion Criteria:

          1. Children ages 7-17 years

          2. Diagnosis of autism per Autism Diagnostic Interview-Revised (ADI-R)

          3. Moderate or Severe GI problems ( on the GSRS, a single score of 4 (severe) on any
             item, or a score of 3 (moderate) on two items, or a score of 2 (mild) or more on any 4
             items

          4. No changes in medications, supplements, diet, therapies, or education in last 3
             months, and no intention to change them during clinical trial

          5. General good physical health aside from gastrointestinal problems

          6. Cognitive Ability to Provide Informed Assent

        Exclusion Criteria:

          1. Antibiotics in last 6 months

          2. Probiotics in last 3 months

          3. Single-gene disorder (Fragile X, etc.)

          4. Major brain malformation

          5. Tube feeding

          6. Severe gastrointestinal problems that require immediate treatment (life-threatening)

          7. Ulcerative Colitis, Crohn's Disease, diagnosed Celiac Disease, Eosinophilic
             Gastroenteritis, or similar conditions

          8. Severely underweight/malnourished

          9. Recent or scheduled surgeries

         10. Current participation in other clinical trials
Clinical trial NCT02510534 (phase 1, status: terminated)
Conditions: pregnancy
ICD codes: O00.00, O00.01, O00.101, O00.102, O00.109, O00.111, O00.112
Drugs: menopur 150 international units, endometrin 100 mg
SMILES: [H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
Reason stopped: 
    unable to enroll participants who meet the criteria
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age 18-37

          -  BMI 19-34 kg/m2

          -  Day 2-3 Follicle stimulating hormone (FSH) less than 10IU/mL

          -  Estradiol (E2) less than 80 pg/mL

          -  Anti-mullerian hormone (AMH) more than 1.5 ng/mL; or antral follicle count (AFC) up to
             10

          -  Two patent fallopian tubes confirmed by hysterosalpingogram (HSG) or chromopertubation

          -  Normal uterine cavity confirmed by HSG, saline sonohysterogram (SIS) or hysteroscopy

        Exclusion Criteria:

          -  Severe male factor (total count less than 10 million sperm)

          -  Systemic diseases not limited to diabetes

          -  Pregnancy within 3 months

          -  More than 1 prior cycle of gonadotropin treatment

          -  Any ovarian cyst >15mm that has persisted for > 1 month

          -  Endometrioma and/or Endometriosis-stage III or IV

          -  Submucosal uterine fibroids; untreated endometrial polyps >1 cm;abnormal reproductive
             tract bleeding

          -  Intolerance or allergy to study drug

          -  Substance abuse (including alcohol and tobacco)

          -  History of chemotherapy (except for gestational conditions) or radiotherapy

          -  Minors and those adults not capable of consenting on their own
Clinical trial NCT02514447 (phase 1/phase 2, status: active, not recruiting)
Conditions: small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: trilaciclib, placebos, topotecan
SMILES: COCCC1=CC=C(OCC(O)CNC(C)C)C=C1, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects aged ≥18 years

          -  Unequivocally confirmed diagnosis of SCLC by histology or cytology, preferably
             including the presence of neuroendocrine features by immunohistochemistry

          -  Progression during or after prior first- or second-line chemotherapy and eligible to
             receive topotecan therapy

          -  At least 1 target lesion that is measurable by RECIST, Version 1.1

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2

          -  Adequate organ function

        Exclusion Criteria:

          -  Presence of symptomatic brain metastases requiring immediate treatment with radiation
             therapy or steroids.

          -  Uncontrolled ischemic heart disease or uncontrolled symptomatic congestive heart
             failure

          -  Known history of stroke or cerebrovascular accident within 6 months prior to
             enrollment

          -  Other uncontrolled serious chronic disease or conditions that in the investigator's
             opinion could affect compliance or follow-up in the protocol

          -  Concurrent radiotherapy to any site or radiotherapy within 2 weeks prior to enrollment
             or previous radiotherapy to the target lesion sites (the sites that are to be followed
             for determination of a response)

          -  Receipt of any investigational medication within 2 weeks prior to enrollment

          -  History of topotecan treatment for SCLC
Clinical trial NCT02515669 (phase 1/phase 2, status: terminated)
Conditions: muscular dystrophy (dmd)
ICD codes: H35.51, L60.3, G71.00, G71.02, G71.11, H35.52, H18.513
Drugs: ro7239361, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    a pre-planned futility analysis indicated lack of efficacy in study nct03039686 and led to
    discontinuation of both ongoing studies in dmd.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with DMD

          -  Able to walk without assistance

          -  Able to walk up 4 stairs in 8 seconds or less

          -  Weigh at least 15 kg

          -  Taking corticosteroids for DMD

        Exclusion Criteria:

          -  Ejection fraction < 55% on echocardiogram, based on central read

          -  Any behavior or mental issue that will affect the ability to complete the required
             study procedures

          -  Previously or currently taking medications like androgens or human growth hormone

          -  Use of a ventilator during the day

          -  Unable to have blood samples collected or receive an injection under the skin

          -  Treatment with exon skipping therapies 6 months prior to study start

          -  Treatment with ataluren or any investigational drug currently or within 5 half-lives
             prior to study start
Clinical trial NCT02528396 (phase 1, status: completed)
Conditions: type 1 diabetes mellitus
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: biochaperone insulin lispro, humalog®
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 1 diabetes mellitus (as diagnosed clinically) ≥ 12 months

          -  Treated with multiple daily insulin injections (no pump users) ≥ 12 months

          -  Current total daily insulin treatment <1.2 (I)U/kg/day

          -  Body mass index (BMI) 18.5-28.0 kg/m² (both inclusive)

          -  HbA1c (N-(1-deoxy)-fructosyl-haemoglobin) ≤ 9.0% by local laboratory analysis

          -  Fasting C-peptide ≤ 0.30 nmol/L

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to trial products or related products

          -  Type 2 diabetes mellitus

          -  Patients using continuous subcutaneous insulin infusion (CSII)

          -  Previous participation in this trial. Participation is defined as randomised

          -  The receipt of any investigational product within 3 months prior to this trial

          -  Clinically significant abnormal haematology, biochemistry, lipids, or urinalysis
             screening tests, as judged by the Investigator considering the underlying disease

          -  Presence of clinically significant acute gastrointestinal symptoms (e.g. nausea,
             vomiting, heartburn or diarrhoea), as judged by the Investigator

          -  Known slowing of gastric emptying and or gastrointestinal surgery that in the opinion
             of the investigator might change gastrointestinal motility and food absorption

          -  Unusual meal habits and special diet requirements or unwillingness to eat the food
             provided in the trial
Clinical trial NCT02532764 (phase 1/phase 2, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: qr-010, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed diagnosis of CF as defined by iontophoretic pilocarpine sweat chloride test
             (sweat chloride) of > 60 mmol/L

          -  Confirmation of CFTR gene mutations homozygous for the ΔF508 mutation

          -  Body mass index (BMI) ≥ 17 kg/m2

          -  Non-smoking for a minimum of two years

          -  FEV1 ≥70% of predicted normal for age, gender, and height, at Screening

          -  Stable lung function

          -  Adequate hepatic and renal function

        Exclusion Criteria:

          -  Breast-feeding or pregnant

          -  Use of lumacaftor or ivacaftor

          -  Use of any investigational drug or device

          -  History of lung transplantation

          -  Hemoptysis
Clinical trial NCT02535104 (phase 1/phase 2, status: completed)
Conditions: condylomata acuminata, papillomavirus infections, sexually transmitted diseases
ICD codes: A64, A63.8
Drugs: ranpirnase, vehicle
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of external genital / perianal warts with at least 2 warts and no more than
             30 lesions

          -  Accept to follow study instructions / signature of IC

          -  Abstain from sexual intercourse for 6 hours after applying the study product during
             the time of the study.

        Exclusion Criteria:

          -  Any topical and/or destructive treatments for external genital warts within 4 weeks
             (within 12 months for imiquimod and within 12 weeks for sinecatechins) prior to
             enrollment (i.e., the randomization visit)

          -  Non pregnant. For women in reproductive age it would be required pregnancy test, and
             the use of double barrier contraceptives.

          -  Any of the following conditions:

          -  Known allergy to the study product

          -  Internal (rectal, urethral) warts that required or were undergoing treatment;

          -  A dermatological disease (e.g., psoriasis) or skin condition in the area, which may
             interfere with the evaluation.

          -  Imiquimod 5% cream (Aldara®)

          -  Any marketed or investigational HPV vaccines

          -  Sinecatechins (Veregen)

          -  Interferon or interferon inducers

          -  Cytotoxic drugs

          -  Immunomodulators or immunosuppressives

          -  Oral or parenteral corticosteroids (inhaled/intranasal steroids are permitted)

          -  Oral antiviral drugs (with the exception of HAART, oral acyclovir and acyclovir
             related drugs) for suppressive or acute therapy herpes; or oseltamivir for prophylaxis
             or for influenza)

          -  Topical antiviral drugs (including topical acyclovir and acyclovir related drugs) in
             the areas under treatment

          -  Podophyllotoxin/Podofilox in the treatment areas

          -  Any topical prescription medications in the treatment areas

          -  Dermatologic procedures or surgery in the treatment areas
Clinical trial NCT02538367 (phase 1/phase 2, status: completed)
Conditions: functional constipation
ICD codes: K59.00, K59.09, K59.01, K59.02, K59.03, K59.04, K58.1
Drugs: yh12852 ir 0.05mg, yh12852 ir 0.1mg, yh12852 ir 0.3mg, yh12852 ir 0.5mg, yh12852 ir 1mg, yh12852 ir 2mg, yh12852 ir 3mg, yh12852 dr1 0.5mg, yh12852 dr1 1mg, yh12852 dr1 2mg, yh12852 dr1 4mg, yh12852 dr2 8mg, prucalopride 2mg, placebo
SMILES: COCCCN1CCC(CC1)NC(=O)C1=C2OCCC2=C(N)C(Cl)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Subjects must be willing and able to provide written informed consent.

          2. BMI within the range 18 to 25 kg/m2.

        Exclusion Criteria:

          1. History of positive serologic evidence for infectious disease including HBsAg,
             anti-HCV, anti-HIV.

          2. Clinically significant lab/ECG abnormalities in the opinion of the investigator.

          3. WOCBP who are unwilling or unable to use an adequate contraceptive method to avoid
             pregnancy for the entire study. WOCBP include any female who has experienced menarche
             and who has not undergone successful surgical sterilization (hysterectomy, bilateral
             tubal ligation, bilateral tubectomy, or bilateral oophorectomy) or is not
             postmenopausal. Post menopause is defined as amenorrhea for ≥ 12 consecutive months
             without another cause.

             Clinically acceptable contraceptive methods for this study: intrauterine devices
             (e.g., loop), physical barrier method (e.g., diaphragm, uterine cap, condom) with
             chemical barrier method (e.g., spermicide), sterile partner, practicing abstinence.

          4. WOCBP who are willing to use hormonal methods or hormone-releasing device(e.g.,
             mirena, implanon) for the entire study.

          5. WOCBP who are pregnant or breastfeeding.

          6. WOCBP with a positive pregnancy test prior to randomization.

          7. Males who have not received a vasectomy must agree to use contraceptive methods
             defined in (a) and refrain from donating sperm throughout the study.

          8. Presence of uncontrolled or severe medical illness.

          9. Presence of a disease that require surgery at any time during the study.
Clinical trial NCT02543918 (phase 1, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: ixekizumab, boostrix®, pneumovax®23
SMILES: [H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy males and females without compromised immune system

          -  Have a body mass Index of 18 to 32 kilograms per square meter (kg/m²)

        Exclusion Criteria:

          -  Previously completed or withdrawn from an ixekizumab study or a study investigating
             interleukin-17 (IL-17) antagonists

          -  Have participated, within the last 30 days, in a clinical trial involving an
             investigational product. If the previous investigational product has a long half-life,
             3 months or 5 half-lives (whichever is longer) should have passed

          -  Have known allergy or hypersensitivity to any biologic therapy

          -  Past vaccination allergy or Arthus-type hypersensitivity

          -  Received a tetanus toxoid-containing vaccine within the last 5 years

          -  Severe allergic reaction to Boostrix

          -  Allergic to latex

          -  Have been immunized with pneumococcal vaccine

          -  Known hypogammaglobulinemia

          -  History of Guillain-Barre Syndrome

          -  Active infectious disease

          -  Had a live vaccination within 1 year prior to screening, or intend to have a live
             vaccination during the course of the study

          -  Evidence of a significant uncontrolled neuropsychiatric disorder -

          -  Have a score of 3 on Item 12 of the Quick Inventory of Depressive Symptomatology-Self
             Report (16 Items) at screening

          -  Evidence of Human Immunodeficiency Virus infection, Hepatitis C, B

          -  Had symptomatic herpes zoster within 3 months of screening

          -  Women who are lactating